<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment protocols for gynecologic malignancies
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment protocols for gynecologic malignancies
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment protocols for gynecologic malignancies
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Tim Brenner, PharmD, BCOP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shrina Duggal, PharmD, BCOP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jim Natale, PharmD, BCOP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Don S Dizon, MD, FACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sadhna R Vora, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 21, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H15357686">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following material represents a subset of chemotherapy and immunotherapy regimens that are used for the treatment of women with gynecologic cancers.
         <strong>
          This is
         </strong>
         <strong>
          not an exhaustive list
         </strong>
         ; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with gynecologic cancers. Additional regimens may be added over time, particularly as treatment for gynecologic cancers evolve.
        </p>
        <p>
         This topic review is intended to provide only a listing of chemotherapy and immunotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with gynecologic cancer. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:
        </p>
        <p class="headingAnchor" id="H15357842">
         <span class="h2">
          Ovarian cancer
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3239.html" rel="external">
          "First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tube, and peritoneal cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3199.html" rel="external">
          "Adjuvant therapy of early-stage (stage I and II) epithelial ovarian, fallopian tube, or peritoneal cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16755.html" rel="external">
          "Medical treatment for relapsed epithelial ovarian, fallopian tube, or peritoneal cancer: Platinum-sensitive disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3240.html" rel="external">
          "Medical treatment for relapsed epithelial ovarian, fallopian tube, or peritoneal cancer: Platinum-resistant disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15358532">
         <span class="h2">
          Endometrial cancer
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16917.html" rel="external">
          "Overview of resectable endometrial carcinoma", section on 'Role of adjuvant therapy'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16721.html" rel="external">
          "Adjuvant treatment of high-risk endometrial cancers"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3186.html" rel="external">
          "Management of locoregional recurrence of endometrial cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15359201">
         <span class="h2">
          Cervical cancer
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3187.html" rel="external">
          "Management of locally advanced cervical cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3185.html" rel="external">
          "Management of recurrent or metastatic cervical cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/13930.html" rel="external">
          "Small cell neuroendocrine carcinoma of the cervix", section on 'Treatment'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/13929.html" rel="external">
          "Invasive cervical adenocarcinoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15359490">
         <span class="h2">
          Uterine sarcoma
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3203.html" rel="external">
          "Clinical features, diagnosis, staging, and treatment of uterine carcinosarcoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3188.html" rel="external">
          "Treatment and prognosis of uterine leiomyosarcoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16903.html" rel="external">
          "Endometrial stromal sarcomas, related tumors, and uterine adenosarcoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In addition, protocols for the treatment of women with sex cord stromal and germ cell tumors are covered separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/85695.html" rel="external">
          "Treatment protocols for germ cell tumors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy and immunotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy and immunotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.
        </p>
        <p class="headingAnchor" id="H15359315">
         <span class="h1">
          REGIMENS
         </span>
        </p>
        <p class="headingAnchor" id="H15359323">
         <span class="h2">
          Regimens for ovarian cancer
         </span>
        </p>
        <p class="headingAnchor" id="H559832070">
         <span class="h3">
          BEP (bleomycin, etoposide, and cisplatin)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef122985" href="/z/d/graphic/122985.html" rel="external">
          table 1
         </a>
         )
        </p>
        <p class="headingAnchor" id="H15359348">
         <span class="h3">
          Cisplatin plus paclitaxel
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef50698" href="/z/d/graphic/50698.html" rel="external">
          table 2
         </a>
         )
        </p>
        <p class="headingAnchor" id="H15359396">
         <span class="h3">
          Carboplatin plus paclitaxel
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef65626" href="/z/d/graphic/65626.html" rel="external">
          table 3
         </a>
         )
        </p>
        <p class="headingAnchor" id="H1067422739">
         <span class="h3">
          Carboplatin plus pegylated liposomal doxorubicin
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef86168" href="/z/d/graphic/86168.html" rel="external">
          table 4
         </a>
         )
        </p>
        <p class="headingAnchor" id="H15359437">
         <span class="h3">
          Gynecologic Oncology Group (GOG) 172 regimen (intravenous [IV] paclitaxel followed by intraperitoneal [IP] cisplatin and IP paclitaxel)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef61475" href="/z/d/graphic/61475.html" rel="external">
          table 5
         </a>
         )
        </p>
        <p class="headingAnchor" id="H1650215328">
         <span class="h3">
          Weekly paclitaxel with every three week carboplatin
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef87790" href="/z/d/graphic/87790.html" rel="external">
          table 6
         </a>
         )
        </p>
        <p class="headingAnchor" id="H1734336749">
         <span class="h3">
          Carboplatin and gemcitabine plus bevacizumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef87827" href="/z/d/graphic/87827.html" rel="external">
          table 7
         </a>
         )
        </p>
        <p class="headingAnchor" id="H15359558">
         <span class="h2">
          Regimens for endometrial cancer
         </span>
        </p>
        <p class="headingAnchor" id="H15359597">
         <span class="h3">
          Carboplatin plus paclitaxel
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef65626" href="/z/d/graphic/65626.html" rel="external">
          table 3
         </a>
         )
        </p>
        <p class="headingAnchor" id="H1380135044">
         <span class="h3">
          Pembrolizumab monotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         This regimen may be administered with the oral agent,
         <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">
          lenvatinib
         </a>
         (
         <a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">
          table 8
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H15359621">
         <span class="h2">
          Regimens for cervical cancer
         </span>
        </p>
        <p class="headingAnchor" id="H934171843">
         <span class="h3">
          Etoposide plus cisplatin (EP)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef63222" href="/z/d/graphic/63222.html" rel="external">
          table 9
         </a>
         )
        </p>
        <p class="headingAnchor" id="H15359662">
         <span class="h3">
          Cisplatin plus paclitaxel
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef50698" href="/z/d/graphic/50698.html" rel="external">
          table 2
         </a>
         )
        </p>
        <p class="headingAnchor" id="H15359703">
         <span class="h3">
          Carboplatin plus paclitaxel
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef65626" href="/z/d/graphic/65626.html" rel="external">
          table 3
         </a>
         )
        </p>
        <p class="headingAnchor" id="H2487579913">
         <span class="h3">
          Pembrolizumab monotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">
          table 8
         </a>
         )
        </p>
        <p class="headingAnchor" id="H15359727">
         <span class="h2">
          Regimens for uterine sarcoma
         </span>
        </p>
        <p class="headingAnchor" id="H1535941416">
         <span class="h3">
          Gemcitabine plus docetaxel
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef58713" href="/z/d/graphic/58713.html" rel="external">
          table 10
         </a>
         )
        </p>
        <p class="headingAnchor" id="H691188789">
         <span class="h2">
          Regimens for microsatellite instability-high cancer
         </span>
        </p>
        <p class="headingAnchor" id="H4165339758">
         <span class="h3">
          Pembrolizumab monotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">
          table 8
         </a>
         )
        </p>
        <p class="headingAnchor" id="H4107285581">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113940.html" rel="external">
          "Society guideline links: Treatment of cervical cancer"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/119533.html" rel="external">
          "Society guideline links: Ovarian, fallopian tube, and peritoneal cancer"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/121144.html" rel="external">
          "Society guideline links: Uterine cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3863150799">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Scott M Wirth, PharmD, BCOP, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div id="topicVersionRevision">
        Topic 85681 Version 23.0
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
